In 2024, global healthcare private equity (PE) reached approximately $115 billion, driven by significant deal activity, particularly in North America, which accounted for 65% of the total. Biopharma led the sector in deal value, supported by major transactions like Catalent and Sanofi’s acquisitions. European deal volumes hit new highs, with a focus on biopharma and medtech. Healthcare IT investments rebounded, spurred by providers and payers seeking efficiency and compliance in operations. The report identifies trends, including mid-market innovation, the rise of carve-outs, and evolving investment landscapes in Asia-Pacific, suggesting a positive outlook for future deal activity.